文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

FP-1201-lyo对比安慰剂治疗中重度ARDS的III期试验方案

Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-11-13

这是一项III期双盲随机平行组试验方案,拟纳入约300例成人中重度ARDS患者,比较静脉注射重组人干扰素β-1a(FP-1201-lyo)10 μg每日一次连续6天与安慰剂的疗效与安全性。主要终点为28天全因死亡与28天内无机械通气天数的复合终点,随访至360天。

要点

  • FP-1201-lyo 10 μg静脉注射每日一次连续6天,对照为安慰剂。
  • 主要终点为28天全因死亡与28天内无机械通气天数的复合终点。
  • 预计样本量300例,在欧洲9国70-80个中心开展。

核心结论

  • 该研究旨在提供FP-1201-lyo改善中重度ARDS患者临床病程与结局的疗效证据。

研究设计与样本

  • III期、双盲、随机、平行组试验,比较FP-1201-lyo与安慰剂在成人ARDS患者中的疗效与安全性。
  • 患者随机接受10 μg FP-1201-lyo或安慰剂静脉注射每日一次连续6天,监测28天或至ICU出院。
  • 随访在第90、180和360天进行;预计样本量300例,在欧洲9国70-80个中心开展。

主要发现

  • 在此前37例ALI/ARDS患者的I/II期开放标签研究中,重组人IFN beta-1a耐受良好,治疗组死亡率显著低于对照组。

关键数值与推荐

  • 主要终点为复合终点,包括28天任何原因死亡和存活者28天内无机械通气天数。
  • 次要终点包括28、90、180和360天全因死亡率、无器官衰竭天数、住院时长、药效学评估(包括黏病毒抵抗蛋白A浓度)以及180和360天生活质量、呼吸和神经功能指标。
  • 样本量估算为300例,用于证明主要结局从30%降至15%的组间差异。

临床怎么用

  • 该方案为ARDS潜在新药FP-1201-lyo的疗效与安全性提供随机对照证据,目前尚无获批的ARDS药物治疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute respiratory distress syndrome (ARDS) results in vascular leakage, inflammation and respiratory failure. There are currently no approved pharmacological treatments for ARDS and standard of care involves treatment of the underlying cause, and supportive care. The vascular leakage may be related to reduced concentrations of local adenosine, which is involved in maintaining endothelial barrier function. Interferon (IFN) beta-1a up-regulates the cell surface ecto-5'-nucleotidase cluster of differentiation 73 (CD73), which increases adenosine levels, and IFN beta-1 may, therefore, be a potential treatment for ARDS. In a phase I/II, open-label study in 37 patients with acute lung injury (ALI)/ARDS, recombinant human IFN beta-1a was well tolerated and mortality rates were significantly lower in treated than in control patients. METHODS/DESIGN: In this phase III, double-blind, randomized, parallel-group trial, the efficacy and safety of recombinant human IFN beta-1a (FP-1201-lyo) will be compared with placebo in adult patients with ARDS. Patients will be randomly assigned to receive 10 μg FP-1201-lyo or placebo administered intravenously once daily for 6 days and will be monitored for 28 days or until discharged from the intensive care unit. Follow-up visits will then take place at days 90, 180 and 360. The primary endpoint is a composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors. Secondary endpoints include: all-cause mortality at 28, 90, 180 and 360 days; organ failure-free days; length of hospital stay; pharmacodynamic assessment including measurement of myxovirus resistance protein A concentrations; and measures of quality of life, respiratory and neurological function at 180 and 360 days. The estimated sample size to demonstrate a reduction in the primary outcome between groups from 30% to 15% is 300 patients, and the study will be conducted in 70-80 centers in nine countries across Europe. DISCUSSION: There are no effective specific treatments for patients with ARDS and mortality rates remain high. The results from this study will provide evidence regarding the efficacy of a potential new therapeutic agent, FP-1201-lyo, in improving the clinical course and outcome for patients with moderate/severe ARDS. TRIAL REGISTRATION: European Union Clinical Trials Register, no: 2014-005260-15 . Registered on 15 July 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bellingan G, Brealey D, Mancebo J, et al. Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29132404. doi:10.1186/s13063-017-2234-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。